Clinical Trials
36
Trial Phases
4 Phases
Drug Approvals
7
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (36 trials with phase data)• Click on a phase to view related trials
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
- Interventions
- Drug: P1446A-05
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 36
- Registration Number
- NCT02117336
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Dartmouth-Hitchcock Norris Cotton Cancer Centre, Lebanon, New Hampshire, United States
Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 100
- Registration Number
- NCT01910571
- Locations
- 🇺🇸
Facility: Profil® Institute for Clinical Research, Inc., Chula Vista, California, United States
A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00
- Conditions
- Radiation Induced Mucositis in Head and Neck Cancer
- Interventions
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 73
- Registration Number
- NCT01903018
- Locations
- 🇮🇳
Bharat Cancer Hospital & Research Institute, Surat, Gujarat, India
🇮🇳Sri Venkateshwara Hospitals, Bangalore, Karnataka, India
🇮🇳Mazumdar Shaw Cancer Center, Bangalore, Karnataka, India
Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2014-08-28
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 96
- Registration Number
- NCT01874366
- Locations
- 🇺🇸
Phase I clinic: MRA Clinical Research, Miami, Florida, United States
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
- Conditions
- Advanced or Inoperable Malignant Melanoma With BRAF Mutation
- Interventions
- Drug: P1446A-05
- First Posted Date
- 2013-04-26
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 100
- Registration Number
- NCT01841463
- Locations
- 🇺🇸
UCSF Medical Center at Mount Zion, South San Francisco, California, United States
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸Georgetown-Lombardi Comprehensive Cancer Ctr, Washington, District of Columbia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next